Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Leukemia

Free Subscription 08.08.2022 2 Acta Haematol 1 Am J Clin Pathol 4 Ann Hematol 8 Blood 1 Bone Marrow Transplant 1 Cancer Res 1 Exp Hematol 2 Int J Hematol 1 J Biol Chem 1 J Clin Oncol 5 Leuk Lymphoma 11 Leukemia

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Haematol

1. DENGLER J, Tesch H, Jentsch-Ullrich K, Gerhardt A, et al
   Treatment-free remission in real-world chronic myeloid leukemia patients: Insights from German hematology practices.
   Acta Haematol. 2022 Jul 29. pii: 000525935. doi: 10.1159/000525935.
   PubMed         Abstract available
   
   
2. BERGER T, Shacham Abulafia A, Shimony S, Pasvolsky O, et al
   Prevalence and Clinical Characteristics of Paraproteinemia Associated with Chronic Myeloid Leukemia.
   Acta Haematol. 2022 Jul 29. pii: 000526168. doi: 10.1159/000526168.
   PubMed         Abstract available
   
   

   
   Am J Clin Pathol

3. KAUMEYER BA, Fidai SS, Thakral B, Wang SA, et al
   GLUT1 Immunohistochemistry Is a Highly Sensitive and Relatively Specific Marker for Erythroid Lineage in Benign and Malignant Hematopoietic Tissues.
   Am J Clin Pathol. 2022;158:228-234.
   PubMed         Abstract available
   
   

   
   Ann Hematol

4. BOEREKAMPS A, Hamberg P, Libourel EJ
   Discontinuation of azacitidine in acute myeloid leukemia: a feasible option?
   Ann Hematol. 2022 Aug 4. pii: 10.1007/s00277-022-04939.
   PubMed        
   
   
5. DONG T, Wu N, Gao H, Liang S, et al
   CD277 agonist enhances the immunogenicity of relapsed/refractory acute myeloid leukemia towards Vdelta2(+) T cell cytotoxicity.
   Ann Hematol. 2022 Aug 3. pii: 10.1007/s00277-022-04930.
   PubMed         Abstract available
   
   
6. AHMED MZ, Venkatadasari I, Dyer S, Wall K, et al
   Clonal evolution in adult TCF3::HLF-positive acute lymphoblastic leukemia undergoing stem cell transplantation.
   Ann Hematol. 2022 Jul 30. pii: 10.1007/s00277-022-04941.
   PubMed        
   
   
7. SEVINDIK OG, Mergen M, Mergen S, Mutlu YG, et al
   To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission.
   Ann Hematol. 2022 Jul 29. pii: 10.1007/s00277-022-04938.
   PubMed        
   
   

   
   Blood

8. BLACK GS, Huang X, Qiao Y, Tarapcsak S, et al
   Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients.
   Blood. 2022;140:401-405.
   PubMed        
   
   
9. LU P, Liu Y, Yang J, Zhang X, et al
   Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial.
   Blood. 2022;140:321-334.
   PubMed         Abstract available
   
   
10. HO JG, Schmidt D, Lowinus T, Ryoo J, et al
    Targeting MDM2 enhances anti-leukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation.
    Blood. 2022 Jul 19. pii: 485955. doi: 10.1182/blood.2022016082.
    PubMed         Abstract available
    
    
11. GERDEMANN U, Alvarez-Calderon F
    Uncovering CD4+ T-cell exhaustion in B-ALL.
    Blood. 2022;140:294-296.
    PubMed        
    
    
12. VELASQUEZ MP, Mamonkin M
    CD7 CAR: sword and shield.
    Blood. 2022;140:293-294.
    PubMed        
    
    
13. CICHOCKI F, Goodridge J, Bjordahl R, Mahmood S, et al
    Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia.
    Blood. 2022 Aug 2. pii: 486089. doi: 10.1182/blood.2021015184.
    PubMed         Abstract available
    
    
14. IACOBUCCI I, Witkowski MT, Mullighan CG
    Single-cell analysis of acute lymphoblastic and lineage ambiguous leukemia - approaches and molecular insights.
    Blood. 2022 Aug 4. pii: 486119. doi: 10.1182/blood.2022016954.
    PubMed         Abstract available
    
    
15. HANDA S, Lee JO, Derkach A, Stone RM, et al
    Long Term Outcomes in Patients with Relapsed or Refractory Hairy Cell Leukemia Treated with Vemurafenib Monotherapy.
    Blood. 2022 Aug 5. pii: 486128. doi: 10.1182/blood.2022016183.
    PubMed         Abstract available
    
    

    
    Bone Marrow Transplant

16. EL CHAER F, Ballen KK
    Measurable residual disease for secondary acute myeloid leukemia prior to allogeneic hematopoietic cell transplantation: does it make a difference?
    Bone Marrow Transplant. 2022 Jul 28. pii: 10.1038/s41409-022-01765.
    PubMed        
    
    

    
    Cancer Res

17. HNATIUK AP, Bruyneel AAN, Tailor D, Pandrala M, et al
    Reengineering Ponatinib to Minimize Cardiovascular Toxicity.
    Cancer Res. 2022;82:2777-2791.
    PubMed         Abstract available
    
    

    
    Exp Hematol

18. LIN C, Xu J, Li N, Li Q, et al
    5-Aza-dC promotes T-cell acute lymphoblastic leukemia cell invasion via downregulation of DNMT1 and upregulation of MMP-2 and MMP-9.
    Exp Hematol. 2022 Jul 28. pii: S0301-472X(22)00579.
    PubMed         Abstract available
    
    

    
    Int J Hematol

19. HAGINO T, Sato T, Saga R, Hidai H, et al
    Myeloid leukemoid reaction after initial azacitidine therapy for chronic myelomonocytic leukemia.
    Int J Hematol. 2022 Jul 19. pii: 10.1007/s12185-022-03422.
    PubMed         Abstract available
    
    
20. LAGANA A, Scalzulli E, Carmosino I, Martelli M, et al
    Asciminib as a third line option in chronic myeloid leukemia.
    Int J Hematol. 2022 Aug 5. pii: 10.1007/s12185-022-03432.
    PubMed         Abstract available
    
    

    
    J Biol Chem

21. ZHUANG H, Ren Y, Mao C, Zhong Y, et al
    Induction of zinc finger protein RNF6 auto-ubiquitination for the treatment of myeloma and chronic myeloid leukemia.
    J Biol Chem. 2022 Aug 1:102314. doi: 10.1016/j.jbc.2022.102314.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

22. SOCIE G
    Long-Term Outcomes After Transplantation for Acute Myelogenous Leukemia.
    J Clin Oncol. 2022 Aug 5:JCO2201177. doi: 10.1200/JCO.22.01177.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

23. SUDUTAN T, Erbilgin Y, Hatirnaz Ng O, Karaman S, et al
    Zinc finger protein 384 (ZNF384) impact on childhood mixed phenotype acute leukemia and B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Aug 3:1-9. doi: 10.1080/10428194.2022.2095630.
    PubMed         Abstract available
    
    
24. PERAGINE N, De Propris MS, Intoppa S, Milani ML, et al
    Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response.
    Leuk Lymphoma. 2022 Aug 1:1-5. doi: 10.1080/10428194.2022.2105324.
    PubMed        
    
    
25. TESTI AM, Al-Jadiry MF, Ghali HH, Fadhil SA, et al
    Childhood acute promyelocytic leukemia in a pediatric cancer referral center in Baghdad, Iraq. Improved results with ATRA extended consolidation.
    Leuk Lymphoma. 2022 Aug 1:1-8. doi: 10.1080/10428194.2022.2105328.
    PubMed         Abstract available
    
    
26. SRINIVASAN S
    Optimal dosing of cytarabine in childhood acute myeloid leukemia: do we have the answer yet?
    Leuk Lymphoma. 2022 Aug 1:1-3. doi: 10.1080/10428194.2022.2105327.
    PubMed        
    
    
27. KUSS B, Nagarajan C, Hsieh WS, Cheah CY, et al
    Practical management of chronic lymphocytic leukemia with acalabrutinib.
    Leuk Lymphoma. 2022 Jul 19:1-10. doi: 10.1080/10428194.2022.2098289.
    PubMed         Abstract available
    
    

    
    Leukemia

28. XIANG P, Yang X, Escano L, Dhillon I, et al
    Elucidating the importance and regulation of key enhancers for human MEIS1 expression.
    Leukemia. 2022;36:1980-1989.
    PubMed         Abstract available
    
    
29. GBADAMOSI MO, Shastri VM, Elsayed AH, Ries R, et al
    A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.
    Leukemia. 2022;36:2022-2031.
    PubMed         Abstract available
    
    
30. KONGKIATKAMON S, Terkawi L, Guan Y, Adema V, et al
    Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms.
    Leukemia. 2022;36:2086-2096.
    PubMed         Abstract available
    
    
31. MEYER AE, Stelloh C, Pulakanti K, Burns R, et al
    Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML.
    Leukemia. 2022;36:2032-2041.
    PubMed         Abstract available
    
    
32. ROHNERT MA, Kramer M, Schadt J, Ensel P, et al
    Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia.
    Leukemia. 2022 Jul 18. pii: 10.1038/s41375-022-01647.
    PubMed         Abstract available
    
    
33. SCHONFELD L, Rinke J, Hinze A, Nagel SN, et al
    ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.
    Leukemia. 2022 Jul 28. pii: 10.1038/s41375-022-01648.
    PubMed         Abstract available
    
    
34. ESCUDERO A, Takagi M, Auer F, Friedrich UA, et al
    Clinical and immunophenotypic characteristics of familial leukemia predisposition caused by PAX5 germline variants.
    Leukemia. 2022 Jul 28. pii: 10.1038/s41375-022-01661.
    PubMed        
    
    
35. ONG JZL, Yokomori R, Wong RWJ, Tan TK, et al
    Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia.
    Leukemia. 2022 Jul 30. pii: 10.1038/s41375-022-01655.
    PubMed         Abstract available
    
    
36. SOVERINI S, De Santis S, Martelli M, Monaldi C, et al
    Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.
    Leukemia. 2022 Jul 30. pii: 10.1038/s41375-022-01660.
    PubMed         Abstract available
    
    
37. FENG P, Chen D, Wang X, Li Y, et al
    Inhibition of the m(6)A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia.
    Leukemia. 2022 Aug 1. pii: 10.1038/s41375-022-01651.
    PubMed         Abstract available
    
    
38. JAHN N, Jahn E, Saadati M, Bullinger L, et al
    Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
    Leukemia. 2022 Aug 3. pii: 10.1038/s41375-022-01650.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: